How Does Mounjaro Work? The Science Behind Tirzepatide, in Plain English

Mounjaro is the brand name for tirzepatide, a once-weekly injection made by Eli Lilly and approved by the FDA in May 2022 for type 2 diabetes. Most people know it as “the other one” next to Ozempic. But it is not a copy of Ozempic with a different logo. It is a different molecule that does a different job inside the body, and the difference starts with which hormones it imitates [1].

This article walks through what the drug actually does, using the FDA-approved prescribing information and the published science as the source. It does not tell you whether to take it or what dose to use. Those are conversations for a healthcare provider.

What is Mounjaro, exactly?

Mounjaro contains tirzepatide, a synthetic peptide 39 amino acids long. The FDA label describes it in one sentence: “Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life” [1].

Unpack that and you get three facts that explain almost everything else:

It copies two hormones, not one. GLP-1 and GIP are both incretins, gut hormones released when you eat. Tirzepatide switches on the receptors for both. Semaglutide, the drug in Ozempic and Wegovy, switches on only the GLP-1 receptor [2].

It is built on the GIP sequence. Researchers at Lilly did not start with GLP-1 and bolt GIP activity onto it. They started with the human GIP peptide and engineered GLP-1 activity into it. The discovery paper puts it exactly that way: tirzepatide “was discovered by engineering GLP-1 activity into the GIP sequence” [3].

A fatty acid chain makes it last a week. A 20-carbon fatty diacid hangs off lysine 20 of the peptide. That greasy tail grabs onto albumin, the most abundant protein in blood. About 99 percent of circulating tirzepatide is stuck to albumin at any moment, and that bound pool acts as a slow-drip reservoir [1]. Without it, the peptide would be gone in minutes.

The label also notes two other engineering tricks: alpha-aminoisobutyric acid, a non-natural amino acid, replaces the normal residues at positions 2 and 13. Position 2 is where an enzyme called DPP-4 normally snips incretin hormones apart within minutes. Blocking that site is what keeps the molecule intact long enough to matter [1].

How does Mounjaro lower blood sugar?

The label lists four separate effects, and they stack.

It makes the pancreas release more insulin, but only when sugar is high

Tirzepatide “enhances first- and second-phase insulin secretion,” the label says, and does so “in a glucose-dependent manner” [1]. First-phase insulin is the quick burst your pancreas fires in the first ten minutes after glucose arrives. In type 2 diabetes that burst is often blunted or missing. Second-phase is the slower, sustained release that follows.

The phrase “glucose-dependent” is the important one. It means the effect switches on when blood sugar is elevated and quiets down when it is not. That is why tirzepatide by itself rarely causes hypoglycemia. The label’s warning about low blood sugar is specifically about combining it with insulin or an insulin secretagogue such as a sulfonylurea, where the label says reducing those other drugs may be necessary [1].

It turns down glucagon

Glucagon is insulin’s opposite number. It tells the liver to dump stored sugar into the blood. In type 2 diabetes, glucagon often stays inappropriately high after meals, which makes post-meal blood sugar worse.

The label quantifies what tirzepatide does: at 15 mg after 28 weeks, fasting glucagon fell 28 percent and glucagon area under the curve after a mixed meal fell 43 percent, with no change in the placebo group [1]. Again, this is glucose-dependent.

It improves insulin sensitivity

This one is less obvious. Beyond squeezing more insulin out of the pancreas, tirzepatide appears to make the body’s tissues respond to insulin better. The label states flatly that “Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study after 28 weeks of treatment” [1].

A 28-week Phase 1 study directly compared tirzepatide 15 mg, semaglutide 1 mg and placebo in people with type 2 diabetes, using gold-standard clamp techniques. Tirzepatide produced significantly greater improvements in clamp-measured insulin sensitivity and in insulin secretion measures than semaglutide did [4].

Part of that comes with weight loss. But mouse work suggests part of it does not. Lilly researchers treated obese mice that had been genetically stripped of the GLP-1 receptor, so tirzepatide could only act through GIP. Those mice lost no weight, yet their insulin sensitivity improved 1.7-fold, traced to glucose being pulled into white fat tissue [5]. That is a mouse result, not a human one, but it is the clearest evidence that the GIP arm of the drug does something the GLP-1 arm cannot.

It slows the stomach, at least at first

Tirzepatide delays gastric emptying, which flattens the spike of sugar that follows a meal. The label is careful about the timing: “The delay is largest after the first dose and this effect diminishes over time” [1].

The measurement behind that sentence used acetaminophen as a marker of how fast the stomach empties. After a first 5 mg dose, peak acetaminophen concentration dropped by about 50 percent and arrived an hour later. By week four, there was no meaningful effect on peak concentration or timing. Total acetaminophen exposure never changed [1].

Research comparing tirzepatide with selective GLP-1 drugs found the gastric effect is comparable, not greater. In mice, tirzepatide slowed emptying about as much as semaglutide, and the effect vanished after two weeks. A long-acting GIP analog by itself had no effect on gastric emptying at all [6]. So the stomach-slowing is a GLP-1 effect, not a GIP one.

What does the GIP part add?

This is the question that makes tirzepatide interesting.

For decades GIP was considered a dead end. Its insulin-releasing power is sharply reduced in people with type 2 diabetes, so activating it looked pointless. Tirzepatide’s clinical results forced a rethink [7].

Three lines of evidence explain what GIP might be contributing:

Fat tissue. Fat cells carry GIP receptors. They do not carry GLP-1 receptors. Lilly’s own laboratory work found that when insulin is present, GIP receptor activation helps fat cells take up glucose and fat; when insulin is low, it pushes fat back out instead. The authors describe it as helping adipose tissue buffer nutrients in both the fed and fasted states [8].

The brain. GIP receptors sit in appetite-controlling regions including the area postrema in the brainstem and the hypothalamus. Mice engineered without brain GIP receptors are protected from diet-induced obesity, and in those mice a GLP-1/GIP dual agonist loses its advantage over a plain GLP-1 agonist [9]. In 2026, researchers narrowed it further: knocking out the GIP receptor specifically in the area postrema abolished the appetite-suppressing effect of a GIP agonist [10].

Tolerability. GIP is anti-nausea in animal models. A small crossover study in 32 healthy volunteers found that pretreating with a selective GIP receptor agonist cut the total number of gastrointestinal side effects from a rapid liraglutide escalation from 75 to 41 [11]. That is a small study of a different molecule, and tirzepatide itself still causes plenty of nausea. But it is a plausible reason why a dual agonist can be pushed to higher effective doses.

Is it really a fifty-fifty split between the two hormones?

No. Tirzepatide is what pharmacologists call an “imbalanced” agonist.

It binds the GIP receptor about as tightly as your own GIP does. It binds the GLP-1 receptor roughly five times more weakly than your own GLP-1 does. In the original measurements, the binding constants were 0.135 nanomolar at the GIP receptor and 4.23 nanomolar at the GLP-1 receptor [3]. Semaglutide, by comparison, is more potent at the GLP-1 receptor than tirzepatide is.

There is a second wrinkle. When tirzepatide switches on the GLP-1 receptor, it drives one internal signaling pathway (cyclic AMP) but barely recruits another (beta-arrestin). Beta-arrestin is the molecule that normally pulls a receptor off the cell surface after it fires. Less beta-arrestin may mean the receptor keeps working longer instead of shutting down. FDA’s own clinical pharmacology review adopts this language, describing tirzepatide as “a biased agonist with preferential signaling towards the activation of adenylyl cyclase as opposed to the recruitment of beta-arrestin” [12].

Whether that bias actually explains any of tirzepatide’s clinical advantage is an open question. Some mouse studies find biased GLP-1 agonists outperform unbiased ones; another found no difference [2]. Cryo-EM structures published in 2022 tied the bias to a combination of the peptide’s GIP-derived first residue and the fatty acid chain [13]. This lane treats it as a strong hypothesis, not a settled fact.

How is Mounjaro taken, and what does the label say about dosing?

Mounjaro is injected under the skin once a week, any time of day, with or without meals, into the abdomen, thigh, or the back of the upper arm (that last one with help from someone else). Sites are rotated with each dose [1].

The label’s escalation schedule starts at 2.5 mg weekly. If more glycemic control is needed, the dosage increases in 2.5 mg steps after at least four weeks on the current dose. The maximum is 15 mg weekly in adults and 10 mg in pediatric patients 10 and older [1]. The label states plainly that the slow climb exists “to reduce the risk of gastrointestinal adverse reactions.”

One detail changed in August 2026. FDA approved a supplement confirming that “the 2.5 mg dose of tirzepatide can be used for ongoing glycemic control in patients with type 2 diabetes mellitus” [14]. That is different from Zepbound, where the label still says 2.5 mg “is for treatment initiation and is not approved as a maintenance dosage” [15]. The label’s exposure-response analysis supports it: 2.5 mg weekly is projected to lower HbA1c by roughly 1.8 percent and fasting glucose by roughly 43 mg/dL at 52 weeks [1].

Missed a dose? The label allows taking it within four days (96 hours). After that it says to skip it and resume on the regular day. The weekly day can be shifted as long as at least three days separate two doses [1]. Semaglutide’s rule is five days, so the two products differ.

Mounjaro comes as single-dose pens, single-dose vials, multi-dose vials and a four-dose KwikPen, all in the same six strengths from 2.5 mg to 15 mg [1].

How long does it take to build up?

Both labels state that steady-state concentrations are reached after four weeks of once-weekly dosing [1]. That reflects a half-life of about five days and roughly 1.7-fold accumulation with repeated dosing [16].

Practically, that means every time the dose goes up, the four-week clock restarts for the new level. It is one reason the label’s minimum interval between increases is four weeks.

What about the heart?

On August 27, 2026, FDA approved a new Mounjaro indication: reducing the risk of major adverse cardiovascular events - cardiovascular death, non-fatal heart attack or non-fatal stroke - in adults with type 2 diabetes at high risk for them [14][17].

The evidence came from SURPASS-CVOT, the first cardiovascular outcomes trial to compare two incretin drugs head to head rather than against placebo. It randomized 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease to tirzepatide (up to 15 mg) or dulaglutide 1.5 mg, and followed them for a median of about four years [18].

A primary event occurred in 12.2 percent of the tirzepatide group and 13.1 percent of the dulaglutide group - a hazard ratio of 0.92, which met the pre-set bar for non-inferiority but not for superiority [18]. At 36 months, weight fell 12.06 percent on tirzepatide versus 4.95 percent on dulaglutide, and HbA1c fell 1.73 percent versus 0.90 percent [17].

It is worth being precise about what that does and does not show. Tirzepatide matched a drug already proven to help the heart. It did not beat it on the primary endpoint. Pharmacists writing about the approval have made the same point: the indication reflects demonstrated non-inferiority to an agent of proven benefit, not evidence that tirzepatide outperforms it.

The bottom line

Mounjaro works by imitating two gut hormones instead of one. The GLP-1 side handles the familiar jobs - more insulin when glucose is high, less glucagon, a slower stomach early on, less appetite. The GIP side adds fat-tissue effects, a separate appetite pathway in the brain, insulin sensitization that does not seem to depend entirely on weight loss, and possibly a bit of anti-nausea cover that lets the drug be pushed further.

It is not a stronger version of semaglutide. It is a different molecule with a different receptor profile, a shorter half-life, and its own label. Anything about whether it is right for a particular person, at what dose, is a question for a healthcare provider.

Sources

1. Mounjaro (tirzepatide) US Prescribing Information, revised 08/2026 - Eli Lilly
2. Insights into the Mechanism of Action of Tirzepatide: A Narrative Review - Diabetes Therapy, 2025
3. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist - Molecular Metabolism, 2018
4. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity - Lancet Diabetes & Endocrinology, 2022
5. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice - JCI, 2021
6. Urva S et al. Tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists - Diabetes, Obesity and Metabolism, 2020
7. Rosenkilde MM et al. GIP Receptor Antagonists in the Pharmacotherapy of Obesity - Diabetes, 2025
8. Regmi A et al. Tirzepatide modulates adipocyte nutrient metabolism through long-acting activation of the GIP receptor - Cell Metabolism, 2024
9. GIP regulates body weight and food intake via CNS-GIPR signaling - Cell Metabolism, 2021
10. Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism - Nature Metabolism, 2026
11. Knop FK et al. A long-acting GIP receptor agonist improves the gastrointestinal tolerability of GLP-1 receptor agonist therapy - Diabetes, Obesity and Metabolism, 2024
12. FDA Clinical Pharmacology Review, NDA 215866 (Mounjaro), 2022
13. Sun B et al. Structural determinants of dual incretin receptor agonism by tirzepatide - PNAS, 2022
14. FDA Supplement Approval Letter, NDA 215866/S-044 and S-045, August 27, 2026
15. Zepbound (tirzepatide) US Prescribing Information, revised 08/2026 - Eli Lilly
16. Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide - CPT: Pharmacometrics & Systems Pharmacology, 2024
17. FDA approves Lilly’s Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes - Eli Lilly, August 28, 2026
18. Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes - NEJM, 2025
19. Hannon TS et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS) - The Lancet, 2025